Kinase Inhibitor Larotrectinib Shows Durable Anti-Tumor Abilities in Patients of All Ages With 17 Unique Cancer Diagnoses
February 21, 2018
February 21, 2018
HOUSTON, Texas, Feb. 21 -- The University of Texas MD Anderson Cancer Center issued the following news release:
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors with tropomyosin receptor kinase (TRK) fusions, gene mutations that switch on TRK genes, allowing cancer growth. The studies indicate larotrectinib as a . . .
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors with tropomyosin receptor kinase (TRK) fusions, gene mutations that switch on TRK genes, allowing cancer growth. The studies indicate larotrectinib as a . . .